Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
20.62 was the low today...
Downside it is!!! 18's should print as we're low 21 now with DOW down over 800 at one point today. I'm tempted to sell 2021 15 puts but depending on panic, that might print too. 8-0
FED did emergency cut .5 and we went from down overall to instant POP and down again, but BHC went to just over 24 and market swings had us back down to 22 today. Roller coaster but this might look like October chart if we get a vaccine soon. Hopefully the cancelled refi gets bigger at a lower rate but the recent selling of shares by insiders (small amounts probably to pay personal taxes in April) never looks good. 22-24 range back in effect but if broken to the upside 26.50 and to downside 18's... HERE WE GO!!!
21.46 today's low for BHC but closed over 23 with DOW almost 1,300 up 5%
FED going to hold and market will fall again. I think they should hold because damage not known yet and we don't need to keep the bubble inflated.
Why BHC is down??? What the hell?
Yeah I guess people are thinking why hold BHC when TSLA and SPCE are going through the roof - 1990s bubble style.
And down more in AH. Another blood bath tomorrow & Tuesday?
Down BHC goes ... down, down, and more down
Bausch Health Companies (NYSE:BHC) Given New $32.00 Price Target at Morgan Stanley
Posted by ABMN Staff on Feb 11th, 2020 // No Comments
Bausch Health Companies logoBausch Health Companies (NYSE:BHC) had its target price dropped by investment analysts at Morgan Stanley from $34.00 to $32.00 in a research report issued to clients and investors on Tuesday, BenzingaRatingsTable reports. The brokerage presently has an “overweight” rating on the stock. Morgan Stanley’s target price would suggest a potential upside of 14.78% from the stock’s current price.
A number of other research firms have also recently issued reports on BHC. Barclays restated a “buy” rating and issued a $33.00 price objective on shares of Bausch Health Companies in a research report on Sunday, January 26th. Piper Jaffray Companies boosted their price target on shares of Bausch Health Companies from $30.00 to $39.00 and gave the company an “overweight” rating in a research report on Monday, December 30th. Zacks Investment Research cut shares of Bausch Health Companies from a “buy” rating to a “hold” rating and set a $33.00 price target on the stock. in a research report on Monday, December 16th. HC Wainwright reiterated a “buy” rating and set a $60.00 price target on shares of Bausch Health Companies in a research report on Monday, December 23rd. Finally, TheStreet upgraded shares of Bausch Health Companies from a “d+” rating to a “c” rating in a research report on Thursday, December 12th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and eleven have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $34.06.
BHC stock opened at $27.88 on Tuesday. The firm’s 50-day moving average price is $28.97 and its two-hundred day moving average price is $25.42. Bausch Health Companies has a 12-month low of $18.72 and a 12-month high of $31.97. The stock has a market capitalization of $9.92 billion, a price-to-earnings ratio of -15.84, a PEG ratio of 0.58 and a beta of 1.02. The company has a current ratio of 1.15, a quick ratio of 0.86 and a debt-to-equity ratio of 9.17.
A number of institutional investors and hedge funds have recently made changes to their positions in BHC. Carolina Wealth Advisors LLC bought a new position in Bausch Health Companies during the fourth quarter valued at approximately $31,000. Bessemer Group Inc. raised its position in Bausch Health Companies by 5,071.8% in the fourth quarter. Bessemer Group Inc. now owns 2,017 shares of the company’s stock worth $60,000 after acquiring an additional 1,978 shares during the period. Aigen Investment Management LP bought a new position in Bausch Health Companies in the fourth quarter worth approximately $95,000. Fieldpoint Private Securities LLC bought a new position in Bausch Health Companies in the fourth quarter worth approximately $104,000. Finally, IFP Advisors Inc raised its position in Bausch Health Companies by 2,293.9% in the fourth quarter. IFP Advisors Inc now owns 3,543 shares of the company’s stock worth $105,000 after acquiring an additional 3,395 shares during the period. Institutional investors and hedge funds own 57.38% of the company’s stock.
About Bausch Health Companies
Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products.
Recommended Story: Most Active Stocks
Analyst Recommendations for Bausch Health Companies (NYSE:BHC)
New highs are needed.
lol back above 30 but on low volume.
Nope, back to $29s already
Maybe it'll stay above $30 this time.
From my view, all news is good for BHC. FDA approvals .. updates to products .. joint efforts with other companies ..
But stock refuses to go UP --- much less shoot UP
.. just sitting around $30 (more like $29)
... O well...
Last rally UP almost hit $32 before dropping to $27s. Hmmmmmmm???
Agree. I think it will take a series of good/great earnings, but should hit $60 by late 2020 imo. BHC in 2020 will be an out an out profitable company (not adjusted earnings). DUOBII should be a big seller (hoping anyway).
Why Bausch Health Still Has More Upside After The Big 32% Rally
Dec. 23, 2019 12:50 PM ET
Positive sentiment for drug stocks is lifting Bausch Health stock, too.
New product launches, licensing, and litigation settlements are positive developments.
Updated price target
I do much more than just articles at DIY Value Investing: Members get access to model portfolios, regular updates, a chat room, and more. Get started today »
Since Sep. 23, 2019, when I called Bausch Health (BHC) a good buy, the stock returned a solid 32.7%. At $29.87 and above my near-term fair value target of $28, investment discipline would dictate automatically selling the stock. But what if fundamentals, sentiment, and facts changed enough in the last quarter? That would justify holding BHC stock for longer.
Bausch stock would have held the $31.97 yearly high if the company did not settle a class action. Although it did not admit any wrongdoing, the company will raise $1.2 billion in debt to drop the suit related to the stock's drop in 2013-2015. Admittedly, I owned BHC stock over a decade ago when the company was known as Biovail Corporation. In that time, a class action settlement netted me a few dollars' worth of settlement. But the ultimate returns came for shareholders later on when Valeant aggressively restructured its business and became Valeant.
Bausch is not yet at a major inflection point to more quickly cut down its debt. Still, it is deploying capital in a disciplined way to slowly increase profitability. Growing its platform in China will more likely net greater returns in the near term. Previously, U.S. and China trade tensions dominated the headlines but it had no effect on the company's prospects in the region. So, expect Bausch management to execute on opportunities that strengthen its business in China.
Debt Reduction
Bausch did a good job cutting debt in the last few years. And because it will use a leverage level, not an absolute dollar level, to set its targets, the company may prioritize growing free cash flow. It will continue to grow its adjusted EBITDA to get there. The next major debt maturity is in 2023-24 when $3.8 billion comes due. Still, the company has three years to grow its core businesses and launch new products. Re-financing at more favorable rates is an option, too, but investors will prefer stronger cash flow growth to take away the concerns of its leverage levels.
Salix Business Worth More
Thankfully, Bausch did not sell its XIFAXAN business in 2016-17 when sales were at its worst. Instead, it invested in the sales team. This resulted in the company executing on stronger sales and driving the asset value higher. Plus, settling with Teva on the patent challenge in Sep. 2018 removed a distraction. Today, it is in a good position in the GI market.
In August, Bausch resolved outstanding intellectual property litigation with Teva for its Apriso drug. Teva will get a non-exclusive license to market a generic version of the drug, which treats ulcerative colitis, starting in Oct. 2021. Bausch changed its sub-license agreement with Lupin Pharmaceuticals, setting the final patent expiry to 2030.
Bausch Health Companies (NYSE:BHC) Price Target Raised to $39.00 at Piper Jaffray Companies
Posted by ABMN Staff on Dec 30th, 2019 // No Comments
Bausch Health Companies logoBausch Health Companies (NYSE:BHC) had its target price raised by equities researchers at Piper Jaffray Companies from $30.00 to $39.00 in a report released on Monday, BenzingaRatingsTable reports. The firm presently has an “overweight” rating on the stock. Piper Jaffray Companies’ target price indicates a potential upside of 31.31% from the company’s previous close.
A number of other brokerages have also issued reports on BHC. ValuEngine lowered Bausch Health Companies from a “sell” rating to a “strong sell” rating in a report on Thursday, October 17th. Barclays boosted their price target on Bausch Health Companies from $28.00 to $30.00 and gave the company an “overweight” rating in a report on Tuesday, November 5th. JPMorgan Chase & Co. upgraded Bausch Health Companies from a “neutral” rating to an “overweight” rating and boosted their price target for the company from $32.00 to $38.00 in a report on Thursday, December 12th. Goldman Sachs Group started coverage on Bausch Health Companies in a report on Monday, December 2nd. They issued a “neutral” rating and a $30.00 price target for the company. Finally, HC Wainwright reiterated a “buy” rating and issued a $60.00 price target on shares of Bausch Health Companies in a report on Monday, December 23rd. Three investment analysts have rated the stock with a sell rating, two have given a hold rating and twelve have given a buy rating to the company’s stock. Bausch Health Companies presently has a consensus rating of “Buy” and an average target price of $32.53.
BHC opened at $29.70 on Monday. The stock has a market cap of $10.47 billion, a price-to-earnings ratio of 7.39, a P/E/G ratio of 0.34 and a beta of 0.90. The stock’s 50 day moving average price is $28.71 and its 200-day moving average price is $24.25. Bausch Health Companies has a one year low of $18.26 and a one year high of $31.97. The company has a debt-to-equity ratio of 9.17, a quick ratio of 0.86 and a current ratio of 1.15.
Bausch Health Companies (NYSE:BHC) last released its earnings results on Monday, November 4th. The company reported $1.19 EPS for the quarter, beating analysts’ consensus estimates of $1.06 by $0.13. The firm had revenue of $2.21 billion for the quarter, compared to analysts’ expectations of $2.15 billion. Bausch Health Companies had a positive return on equity of 56.19% and a negative net margin of 7.25%. As a group, analysts predict that Bausch Health Companies will post 4.38 earnings per share for the current fiscal year.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in BHC. Vanguard Group Inc. grew its position in Bausch Health Companies by 4.0% during the 2nd quarter. Vanguard Group Inc. now owns 9,513,863 shares of the company’s stock worth $239,940,000 after purchasing an additional 363,579 shares during the period. Renaissance Technologies LLC boosted its stake in shares of Bausch Health Companies by 9.8% during the 2nd quarter. Renaissance Technologies LLC now owns 3,037,200 shares of the company’s stock worth $76,598,000 after acquiring an additional 272,000 shares in the last quarter. Ardevora Asset Management LLP boosted its stake in shares of Bausch Health Companies by 7.1% during the 3rd quarter. Ardevora Asset Management LLP now owns 1,916,320 shares of the company’s stock worth $41,872,000 after acquiring an additional 127,800 shares in the last quarter. Cannell Peter B & Co. Inc. boosted its stake in shares of Bausch Health Companies by 112.4% during the 2nd quarter. Cannell Peter B & Co. Inc. now owns 1,515,215 shares of the company’s stock worth $38,214,000 after acquiring an additional 801,760 shares in the last quarter. Finally, MUFG Securities EMEA plc boosted its stake in shares of Bausch Health Companies by 72.0% during the 2nd quarter. MUFG Securities EMEA plc now owns 1,486,700 shares of the company’s stock worth $37,495,000 after acquiring an additional 622,200 shares in the last quarter. 57.51% of the stock is currently owned by hedge funds and other institutional investors.
Bausch Health Companies Company Profile
Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products.
I guess I am going to have good Christmas!
Bausch Health in-licenses dry eye candidate from Novaliq GmgH
Dec. 20, 2019 8:47 AM ET|About: Bausch Health Companie... (BHC)|
By: Douglas W. House, SA News Editor
Bausch Health Companies (NYSE:BHC) unit Bausch + Lomb inks an agreement with Heidelberg, Germany-based Novaliq GmbH for exclusive U.S. and Canadian rights to NOV03 (perfluorohexyloctane) for the potential treatment of dry eye disease associated with Meibomian gland dysfunction (gland that secretes oils onto the surface of the eye).
Under the terms of the deal, Novaliq will receive upfront and milestone payments and royalties on net sales. Specific financial terms are not disclosed. BHC has the right to pursue additional ophthalmic indications for NOV03, alone and in combination (Novaliq will be eligible for additional payments and royalties for the combo products).
A Phase 2 trial was successful, achieving the primary endpoint of a statistically significant improvement of total corneal fluorescein staining at week 8 versus placebo.
A Phase 3 study is in process. BHC plans to start another Phase 3 in 2020.
Agree. Hit $30.18 today.
Nice rebound from the past 3 days of falling.
Mdb1l hope you are right for 2020, right now is going down hopefully it ll stop soon!
I think still headed to $60s next year. imo all the "news" is still good.
This is the expected consolidation after going straight up $12 from $19s
Unfortunately our good days are over, with new debt ll go down again, probably to mid 20ies.
We are now in uncharted territory for BHC. It is has been setting over 3 year highs almost every day now (intra-day highs) :: So far a sustained upward trend from $19s to $31s.
BHC has been a horse recently. No tax loss selling this year
No worries about BHC, worries are behind, next 4th quarter earnings which ll be very good and move very much above 30 up!
Almost hit $32 today before dropping. At least so far.
I am waiting for 48$ in few months.
What a breakout from $19s. Who knew. $60s next year anyone?
woohooo I wish I had bought more ! I may have to put a stop underneath my shares soon.
JP Morgan moves price target to 38
Pre-market: $30.05. Is today the day of $30s ??????
Where O where are those $30s BHC ???????????
It might finally hit 30$ !
BHC going UP. Stock highest in over 3 years.
Does BHC spike to $30 today -- even for a brief second?
$30s and beyond. Upward trend continues, albeit at a much slower pace.
I was waiting for this day long time! Next $30!
So far up on a market down day: $28s still. Didn't crash down to $22s this time. Hmmm?
Followers
|
92
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
5018
|
Created
|
05/15/08
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |